These datacorresponds well with a subgroup analysis of the RE-LY [12], which demonstrated that 150 mg dabigatran wasnot superior at reducing the risk of stroke at higher TTR setting, as in ourwarfarin cohort. This evidence concerns the gene TTR and stroke disorder.